1-3 of 3
Ramona Schlenker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2342: RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers

Free
Carles Fabregat-Franco, Changhoon Yoo, Bruno Sangro, Camilla Qvortrup, Hyung-Don Kim, Teresa Macarulla, Mariano Ponz-Sarvisé, Chia-Chi Lin, Do-Youn Oh, Thomas Yau, Juliana Bessa, Petra C. Schwalie, Steffen Dettling, Ramona Schlenker, Natascha Riede, Elia Hall, Felix Lichtenegger, Nicole Kratochwil, Thomas Pöschinger, Zhiwen Jiang, Tianyi Jiang, Christina Godfried Sie, Audrey Yeo Te-Ying, Christina Schiff, Sabine Hoves, Michael Cannarile
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2342.
https://doi.org/10.1158/1538-7445.AM2023-2342
Published: 04 April 2023
View articletitled, Abstract 2342: RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers
Journal Articles

Abstract 1552: A novel PD1-IL2v immunocytokine for preferential cis-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism

Free
Christian Klein, Laura Codarri-Deak, Valeria Nicolini, Stefan Seeber, Laura Lauener, Marine Richard, Esther Bommer, Maria Karagianni, Johannes Sam, Ramona Schlenker, Marisa Mariani, Petra Petra Schwalie, Sylvia Herter, Marina Bacac, Inja Waldhauer, Anne Freimoser-Grundschober, Volker Teichgraeber, Pablo Umana
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1552.
https://doi.org/10.1158/1538-7445.AM2019-1552
Published: 01 July 2019
View articletitled, Abstract 1552: A novel PD1-IL2v immunocytokine for preferential cis-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism
Journal Articles

Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy

Free
Ramona Schlenker, Luis Felipe Olguín-Contreras, Matthias Leisegang, Julia Schnappinger, Anja Disovic, Svenja Rühland, Peter J. Nelson, Heinrich Leonhardt, Hartmann Harz, Susanne Wilde, Dolores J. Schendel, Wolfgang Uckert, Gerald Willimsky, Elfriede Noessner
Journal: Cancer Research
Series: Author Choice
Cancer Res (2017) 77 (13): 3577–3590.
https://doi.org/10.1158/0008-5472.CAN-16-1922
Published: 02 July 2017
View articletitled, Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
Open the PDF for Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy in another window
Includes: Supplementary data